Tucidinostat

Generic Name: Tucidinostat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉FN_₄O_₂

CAS Number: 1616493-44-7

Unique Ingredient Identifier: 87CIC980Y0

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Phase 2

Recruiting

Conditions: Solid Tumor
Precision Medicine

Interventions: Drug: Target Gene
Drug: Olaparib tablet
Drug: Temozolomide capsule
Drug: Anlotinib
Drug: Trametinib tablet
Drug: Dabrafenib
Drug: Vebreltinib Enteric Capsules
Drug: Alpelisib Pill
Drug: Sacituzumab Govitecan-Hziy 180 MG
Drug: Lenvatinib Capsules
Drug: Pazopanib Pill
Drug: Palbociclib Pill
Drug: Chidamide
Drug: PD-1/PD-L1/PD-1&CTLA4 inhibitor

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 300

Registration Number: NCT06739395

Locations: 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Fruquintinib
Drug: Sintilimab
Drug: Chidamide

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-20

Lead Sponsor: Dai, Guanghai

Target Recruit Count: 46

Registration Number: NCT06685276

Locations: 🇨🇳
China PLAGH, Beijing, China

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Phase 2

Not yet recruiting

Conditions: Diffuse Large B-Cell Lymphoma-Refractory
Diffuse Large B-Cell Lymphoma-Recurrent

Interventions: Drug: Glofitamab
Drug: Chidamide

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 22

Registration Number: NCT06570447

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, China

Exploration of Dalpiciclib + Tucidinostat in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Phase 2

Not yet recruiting

Conditions: HR+/HER2- Advanced Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Tucidinostat

First Posted Date: 2024-08-16

Last Posted Date: 2024-08-16

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 155

Registration Number: NCT06556862

Locations: 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

Phase 2

Active, not recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Chidamide

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-29

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 35

Registration Number: NCT06550336

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Phase 2

Not yet recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Polatuzumab vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Orelabrutinib
Drug: Venetoclax
Drug: Chidamide
Drug: Penpulimab
Drug: Lenalidomide

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 528

Registration Number: NCT06516978

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tucidinostat
Drug: Fruquintinib
Drug: Sintilimab
Drug: Bevacizumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-12-03

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 430

Registration Number: NCT06497985

Locations: 🇨🇳
Rui-Hua Xu, Guangzhou, Guangdong, China

Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: PTCL

Interventions: Drug: Toripalimab
Drug: chidamide

First Posted Date: 2024-07-09

Last Posted Date: 2024-07-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 43

Registration Number: NCT06492629

Locations: 🇨🇳
Department of Medical Oncology, Beijing, Beijing, China

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Phase 2

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Anthracyclines or anthraquinones
Drug: Chidamide
Drug: Venetoclax
Drug: cytarabine
Drug: azacitidine

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-11

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 240

Registration Number: NCT06451861

Locations: 🇨🇳
Foshan First People's Hospital, Foshan, Guangdong, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 10 locations

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Not Applicable

Not yet recruiting

Conditions: Acute Myeloid Leukemia
AML

Interventions: Drug: Chidamide
Drug: Venetoclax
Drug: azacitidine

First Posted Date: 2024-04-26

Last Posted Date: 2024-04-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 184

Registration Number: NCT06386302

Locations: 🇨🇳
Blood Hospital, Tianjin, Tianjin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy